While GLP-1 agonists are clinically indicated for weight reduction, this finding likely reflects selection bias, wherein providers may preferentially prescribe GLP-1s to patients with more severe obesity or to those who have not responded to other treatment options. This evidence concerns the gene GLP1R and obesity disorder.